Skip to main content

Table 1 Associations between median cancer CXCL13 expression and patient and tumor characteristics

From: Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Characteristic PatientsNumber (percentage) Cancer CXCL13 content P
≤ MedianNumber (percentage) > MedianNumber (percentage)
Tumor size
 pT1 368 (41.8) 172 (46.7%) 196 (44.7%)  
 pT2 437 (49.6) 226 (51.7%) 211 (48.3%)  
 pT3 76 (8.6) 45 (59.2%) 31 (40.8%) 0.099
 Missing data 1    
Axillary nodal status
 pN0 93 (10.6) 45 (48.4%) 48 (51.6%)  
 pN1 761 (86.4) 384 (50.5%) 377 (495%)  
 pN2 27 (3.1) 14 (51.9%) 13 (48.1%) 0.922
 Missing data 1    
Histological grade
 I 127 (15.0) 84 (66.1%) 43 (33.9%)  
 II 352 (41.6) 196 (55.7%) 156 (44.3%)  
 III 368 (43.4) 147 (39.9%) 221 (60.1%) < 0.001
 Missing data 35    
Age at study entry
  <50 years 393 (44.6) 168 (42.7%) 225 (57.3%)  
 ≥50 years 489 (55.4) 275 (56.2%) 214 (43.8%) < 0.001
Estrogen receptor status
 Positive 635 (72.0) 360 (56.7%) 275 (43.3%)  
 Negative 247 (28.0) 83 (33.6%) 164 (66.4%) < 0.001
Progesterone receptor status
 Positive 510 (57.9) 273 (53.5%) 237 (46.5%)  
 Negative 371 (42.1) 170 (45.8%) 201 (54.2%) 0.025
 Missing data 1    
HER2 status
 Positive 199 (22.6) 80 (40.2%) 119 (59.8%)  
 Negative 683 (77.4) 363 (53.1%) 320 (46.9%) 0.002
Ki-67
 ≤20% (median) 396 (50.5) 219 (55.3%) 177 (44.7%)  
 >20% 388 (49.5) 161 (41.5%) 227 (58.5%) < 0.001
 Missing data 98    
Molecular subtype
 Luminal A-like 331 (40.8) 190 (57.4%) 141 (42.6%)  
 Luminal B-like 148 (18.2) 77 (52.0%) 71 (48.0%)  
 Triple-negative 134 (16.5) 47 (35.1%) 87 (64.9%)  
 HER2-positive 199 24.5) 80 (40.2%) 119 (59.8%) < 0.001
 Missing data 70    
Assigned chemotherapy
 Vinorelbine 437 (49.5) 210 (48.1%) 227 (51.9%)  
 Docetaxel 445 (50.5) 233 (52.4%) 212 (47.6%) 0.225
Trastuzumab given (if HER2+) cancers)
 Yes 103 (52.2) 41 (39.8%) 62 (60.2%)  
 No 94 (47.7) 38 (40.4%) 56 (59.6%) 0.522
  1. Abbreviations: CXCL13 C-X-C motif chemokine ligand 13, HER2 human epidermal growth factor receptor 2
\